Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 16/20 | 0.53 |
| ▸ | GRK3 | P35626 | 7/20 | 0.53 |
| ▸ | GRK5 | P34947 | 4/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972318 | 0.90 | RAF1 (0.48) | GRK2GRK3RAF1ROCK2LMNA | |
| SCHEMBL4443071 | 0.83 | RAF1 (0.61) | GRK2GRK3RAF1RIPK2KDR | |
| SCHEMBL4442571 | 0.77 | RAF1 (0.62) | GRK2GRK3GRK5RAF1ROCK2 | |
| SCHEMBL13823410 | 0.73 | RAF1 (0.50) | GRK2GRK3RAF1ROCK2RIPK2 | |
| SCHEMBL14136181 | 0.73 | RAF1 (0.50) | GRK2GRK3RAF1ROCK2LMNA | |
| SCHEMBL4444438 | 0.72 | RAF1 (0.72) | RAF1RIPK2KDR | |
| SCHEMBL4443422 | 0.70 | GRK2 (0.50) | GRK2GRK3GRK5RAF1ROCK2 | |
| SCHEMBL14496421 | 0.69 | GRK2 (1.00) | GRK2GRK3GRK5ROCK2LMNA | |
| SCHEMBL4442586 | 0.69 | RET (0.58) | GRK2RAF1LMNARIPK2KDR | |
| SCHEMBL3594471 | 0.68 | IMPDH2 (0.58) | GRK2GRK3GRK5ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | ARAF, BRAF, RAF1 | GRK2 151/4885GRK3 114/4885GRK5 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.